Goldman Sachs Downgrades Esperion Therapeutics (ESPR) to Sell Amid Ongoing Launch Headwinds and Lack of Catalysts
Tweet Send to a Friend
(Updated - February 9, 2021 5:52 AM EST)Goldman Sachs analyst Paul Choi downgraded Esperion Therapeutics (NASDAQ: ESPR) from Neutral to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
